Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 8/20 | 0.54 |
| ▸ | MAPT | P10636 | 8/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.34 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11976206 | 0.94 | AHCY (0.54) | AHCYMAPTPOLB | |
| SCHEMBL11974075 | 0.92 | AHCY (0.46) | AHCYMAPTTP53 | |
| SCHEMBL13652608 | 0.91 | AHCY (0.44) | AHCYMAPTPOLBPLA2G1BATG4B | |
| SCHEMBL11976141 | 0.88 | AHCY (0.53) | AHCY | |
| SCHEMBL11974610 | 0.87 | AHCY (0.53) | AHCYMAPT | |
| SCHEMBL11974810 | 0.86 | AHCY (0.46) | AHCYMAPTTP53 | |
| SCHEMBL11975615 | 0.85 | AHCY (0.56) | AHCYPOLB | |
| SCHEMBL11974688 | 0.85 | AHCY (0.53) | AHCYTP53 | |
| SCHEMBL11975575 | 0.84 | AHCY (0.54) | AHCYPOLB | |
| SCHEMBL11975774 | 0.84 | AHCY (0.50) | AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| WO-2011043479-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | 田辺三菱製薬株式会社 (JP) | 2011-04-14 | — | — | WO | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | AHCY 4108/4885MAPT 230/4885POLB 4635/4885 |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | BHMT, CBS, BHMT2 | AHCY 4/4885MAPT 1767/4885POLB 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.